

HIV-1 vaccine components facilitate the production of virus-like particles (VLPs) and the presentation of envelope proteins that reveal broadly neutralizing epitopes.

Pamila Kranca Bosengarten

***Corresponding author**

Pamila Kranca Bosengarten,
Research Group Pharmaceutical Biotechnology, Faculty of
Applied Natural Sciences, TH Koln - University of Applied
Sciences, Germany.

Received Date : May 23, 2024

Accepted Date : May 25, 2024

Published Date : June 25, 2024

ABSTRACT

Developing a preventive vaccination is hampered most by the sequence variety of HIV-1. Trialists are currently testing Mosaic (Mos) antigens, which are made up of artificially scrambled epitopes from different strains of HIV-1 (NCT03964415). The Mosaico vaccine includes vectors that mediate gene transfer and production of the membrane-anchored Env-variant Mos2S.Env in addition to adenovirus vectors encoding variations of the Mos.Gag-Pol and soluble Mos.Env proteins. Therefore, we investigated whether the production of virus-like particles (VLPs) is mediated by the expression of mosaic Gag. The Mos1.Gag- and Mos2.Gag-VLP-formation was easily identified using electron microscopy and Western blot analysis. Co-expression of Mos2S.Env and both mosaic Gag variants resulted in the integration of Env into Gag-formed VLPs. Mos2S.Env-decorated VLPs were shown to display the corresponding neutralization-sensitive target epitopes when a panel of broadly neutralizing antibodies (bNAbs) was used in a VLP-capture test. This provides fresh insights for developing HIV vaccines in the future.

KEYWORDS

Vaccine development, Mosaic HIV-1 antigens p55-gag virus-like particles, Broadly neutralizing antibodies, PiggyBac transposon vectors, Suspension cell lines

INTRODUCTION

It is vitally necessary to create a preventive vaccination in order to fight the HIV/AIDS epidemic. A perfect vaccination would stimulate humoral as well as cellular immunity. However, the development of a vaccine is severely hampered by the great genetic heterogeneity of HIV-1 (Gaschen et al., 2002; Ndung'u and Weiss, 2012). To reduce the number of infected cells and, consequently, the viral load, a robust T cell response—especially one that involves CD8⁺ cytotoxic T lymphocytes (CTLs)—must be triggered (Kiepiela et al., 2007; Janes et al., 2017; Collins et al., 2020). Furthermore, in order to prevent virus cell entrance, a strong vaccination must stimulate the production of broadly neutralizing antibodies (bNAbs) against neutralization-sensitive epitopes found in the viral envelope glycoproteins (Env) (Zolla-Pazner et al., 2014; So-called mosaic (Mos) HIV antigens, which are composed of artificially shuffled epitope sequences coming from several HIV variations, were created to increase coverage of potential T and B cell epitopes originating from diverse HIV variants (Fischer et al., 2007). When rhesus macaques were vaccinated with an adenovirus vector containing the antigen-encoding genes Mos.Gag, Mos.Pol, and Mos.Env, the results showed that the antigen-specific T cell responses were more extensive and varied than when utilizing consensus or naturally occurring sequences (Barouch et al., 2010). These results served as the foundation for the ongoing Mosaico clinical trial (NCT03964415). In addition to soluble Env proteins acting as booster vaccine subunit components, the adenovirus vector components Ad26.Mos1.Gag-Pol, Ad26.Mos2.Gag-Pol, Ad26.Mos1.Env, and Ad26.Mos2S.Env are part of the Ad26.Mos4 tetravalent vaccination (Ad26.Mos4) for HIV (Baden et al., 2020). Mos2S.Env, also known as C4D7, is membrane-anchored because it possesses a transmembrane region, in contrast to the soluble Mos1.Env. When compared to its full-length counterpart, the shortened cytoplasmic tail (CT) of Mos2S.Env was demonstrated to enhance surface expression (Langedijk et al., 2019, 2021). The ability of the artificial mosaic Gag variations to promote the generation of virus-like particles (VLPs), as seen with naturally occurring Gag precursor proteins (Gheysen et al., 1989; Konnyu et al., 2013), has not yet been investigated. Following the administration of the tetravalent

vaccine Ad26.Mos4.HIV, vaccination recipients may develop VLPs. VLPs significantly increase cellular.

To evaluate the capacity of mosaic antigens to generate vector lip products (VLPs), we generated viable human suspension cell lines that expressed either Mos1.Gag and Mos2.Gag alone or in combination with Mos2S.Env. Transposon vectors generated from piggyBac were created and then transfected 293-F cells in order to accomplish this. This method was used since transposon vectors have been demonstrated in the past to facilitate the quick establishment of recombinant cell lines that produce particles derived from viruses (Lynch et al., 2010; Berg et al., 2019; van Heuvel et al., 2021). Cell-free supernatants were pelleted using ultracentrifugation, and the resulting pellets were submitted to Western blot and electron microscopic examination to determine if bald and Env-decorated VLPs were generated.

Additionally, bNAbs were used in VLP capture tests to precipitate VLPs that were likely to have epitopes responsive to neutralization. VLPs with precipitated env-positive.

RESULTS

The initial evidence that the expression of both Mos1.Gag and Mos2.Gag, respectively, in the absence or presence of Mos2S. Env were able to mediate VLP-formation came from transient transfection experiments using HEK293T cells and the described transposon vectors containing mos1.gag, mos2.gag, and mos2s.env. Using a p24-specific ELISA, it was discovered that cell-free supernatants three days after transfection contained up to 110 ng/mL of gag (data not shown). Transposon-mediated gene transfer was used to quickly establish cell lines that persistently expressed the mosaic HIV genes, demonstrating the formation of VLPs and facilitating in-depth study. The very active piggyBac transposase is made possible by CMVhyPBBase, as shown in Fig. 1 (Yusa et al., 2011). For each mosaic, the transposon constructions PB-Mos1.Gag-IpW and PB-Mos2.Gag-IpW encode gag genes connected to puromycin resistance gene expression. Vector donor PB-Mos2S.Env consists of the hygromycin resistance gene connected to the mosaic env gene. The suspension cells of human 293-F were.

The aforementioned VLP samples were also submitted to Western blot-analysis employing polyclonal antibodies directed against the surface unit gp120-SU of HIV-1 Env in order to investigate the possible inclusion of Mos2S.Env into mosaic Gag-formed VLPs. Negative controls were samples of uninfected 293-F cells and cells that expressed just Gag variations, respectively. Mos2S.Env proteins were easily and only found in VLPs made by gag- and env-transgenic cells, as shown in Fig. 3. by the cellular furin-like proteases (McCune et al., 1988; Hallenberger et al., 1992; Decroly et al.,

1994). of the precursor proteins. There were no signs of Env degradation products.

The levels of Env protein found were similar. This demonstrated that Mos2S.Env was effectively incorporated into VLPs created by both mosaic Gag proteins. Remarkably, extremely few amounts of the unprocessed precursor gp140-Pr proteins were found, whereas the great majority of Env identified were fully processed, and hence soluble, gp120-SU proteins. This demonstrated the extremely effective processing.

We created a piggyBac-derived transposase construct and three transposon vectors encoding Mos1.Gag, Mos2.Gag, and Mos2S.Env, respectively, to quickly establish stable human 293-F suspension producer cell lines upon co-transfection and selection in order to investigate VLP-formation mediated by mosaic gene expression. Using negative stain transmission electron microscopy (TEM) analysis, VLPs were easily identified when Mos1.Gag, Mos2.Gag, and Mos2S were expressed exclusively. These results are consistent with other studies (Chapman et al., 2017) that showed mosaic Gag sequences might induce VLPformation following expression in human cells.

Following co-transfection of cells with mosaic gag and chimeric env plasmid vectors and infection of cells with MVA vaccines, Chapman and colleagues have previously shown the in vivo formation of Env-decorated mosaic Gag VLPs.

cleaves Gag into its subunit components, a process that would be mediated by the viral protease and included in the Ad26.Mos4.HIV vaccine. On the other hand, this should have a favorable impact on the particles' immunogenicity and, thus, their potential as vaccine ingredients. In a comparative investigation using DNA/MVA vaccinations in rhesus monkeys, Ellenberger and colleagues reported on the enhanced immunogenicity of mature as opposed to immature VLPs (Ellenberger et al., 2005).

MATERIALS AND METHODS

The transposon donor vectors and the transposase construct had nearly identical genomic designs with the vectors derived from Sleeping Beauty that we previously reported (Berg et al., 2019, 2020). The PB-CAG-DDdCas 9VP192-T2A-GFP-IRES-Neo, a generous donation from Timo Otonkoski (plasmid no.102885; Addgene, USA), provided the DNA sequences for the piggyBac ITRs. After being synthesized (GenScript, USA), the ITRs were introduced into pUC57 to create pUC57-piggyBacITRs. Using FseI restriction sites, the transgene expression cassettes of the donor vectors SB-IpW and SB-IhW, which were generated from Sleeping Beauty, were introduced into pUC57-piggyBacITRs to produce PB-IpW and PB-IhW, respectively. Using codon optimization for human and Chinese hamster ovary cells, the genes encoding Mos1.Gag, Mos2.Gag, and Mos2S.Env, respectively, were synthesized (GenScript, USA) and inserted

into pUC57. Human suspension 239-F cells (Thermo Fisher Scientific Cat #R79007, RRID: CVCL_D603, USA) were used in all investigations.

expanded in Thermo Fisher Scientific's (293F-FreeStyle-Expression-Medium, USA) serum-free formulation. In order to generate stable VLP producer cells, 293-F cells were co-transfected with the transposase construct and one of the gag-expressing transposon vectors, or both in conjunction with the transposon vector encoding Mos.2SEnv. As previously mentioned (Berg et al., 2020), 293-F cells were transfected using 1 g/L polyethylenimine (PEI; MW 40,000; Polysciences, USA) and then stable cell lines were chosen. In summary, 50 µg of plasmid DNA total was utilized for transfection, and the hypBase construct was always used in a 1:1:4 ratio with Gag expressing transposon vectors. consistent producing cell lines that express Gag and Env were created via transfection at a 1:2:2 ratio. A moderate selection pressure was applied four days after transfection (dpt) utilizing doses of 4 µg/mL puromycin, or equivalently, 4 µg/mL puromycin combined with 50 µg/mL hygromycin. Antibiotic concentrations were continuously raised. Starting at day 21, recombinant cell lines were maintained under continuous selection pressure with 200 µg/mL hygromycin, 10 µg/mL puromycin, and 15 µg/mL puromycin, respectively. Using 250–500 mL disposable shaker flasks with vent lids (Nalgene Nunc International, USA), cultivation was done in quantities of 50–200 mL media at starting cell densities of 0.6 x 10⁶ cells/mL. A Minitron shaker incubator with an 8% CO₂ atmosphere, 37 °C, and 135 rpm was used for the incubation.

Acknowledgment

The CECAD Cologne Imaging Facility's Beatrix Martiny and Astrid Schauss provided superb sample preparation and electron microscopic examination of virus-like particles, for which the authors are grateful. The German Federal Ministry of Education and Research provided financing for this work under the funding program Forschung a Fachhochschulen; SB and JS's contracts with the ministry were 13FH767IA6 and 13FH242PX6, respectively.

REFERENCES

1. Abad, J.L., et al., 2002. Single-step, multiple retroviral transduction of human T cells. *J. Gene Med.* 4 (1), 27–37. <https://doi.org/10.1002/jgm.242>.
2. Bachmann, M.F., et al., 1993. The influence of antigen organization on B cell responsiveness. *Science* 262 (5138), 1448–1451. <https://doi.org/10.1126/science.8248784>.
3. Bachmann, M.F., Jennings, G.T., 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. *Nat. Rev. Immunol.* 10 (11), 787–796. <https://doi.org/10.1038/nri2868>.
4. Baden, L.R., et al., 2020. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVVERSE): a randomised, parallel group, placebo-controlled, double-blind, phase 1/2a study. *The Lancet HIV* 7 (10), e688–e698. [https://doi.org/10.1016/S2352-3018\(20\)30229-0](https://doi.org/10.1016/S2352-3018(20)30229-0).
5. Barouch, D.H., et al., 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. *Nat. Med.* 16 (3), 319–323. <https://doi.org/10.1038/nm.2089>.
6. Bellier, B., et al., 2006. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. *Vaccine* 24 (14), 2643–2655. <https://doi.org/10.1016/j.vaccine.2005.11.034>.
7. Beltran-Pavez, C., et al., 2021. Potent induction of envelope-specific antibody responses by virus-like particle (VLP) immunogens based on HIV-1 envelopes from patients with early broadly neutralizing responses. *J. Virol.* <https://doi.org/10.1128/JVI.01343-21>.
8. Berg, K., et al., 2019. Rapid establishment of stable retroviral packaging cells and recombinant susceptible target cell lines employing novel transposon vectors derived from Sleeping Beauty. *Virology* 531, 40–47. <https://doi.org/10.1016/j.virol.2019.02.014>.
9. Berg, K., et al., 2020. Advanced establishment of stable recombinant human suspension cell lines using genotype–phenotype coupling transposon vectors. In: Zielonka, S., Krah, S. (Eds.), *Methods in Molecular Biology*. Springer US (Methods in Molecular Biology), New York, NY, pp. 351–361. https://doi.org/10.1007/978-1-4939-9853-1_20.
10. Buchacher, A., et al., 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and epstein-barr virus transformation for peripheral blood lymphocyte immortalization. *AIDS Res. Hum. Retrovir.* 10 (4), 359–369. <https://doi.org/10.1089/aid.1994.10.359>.
11. Caskey, M., et al., 2017. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. *Nat. Med.* 23 (2), 185–191. <https://doi.org/10.1038/nm.4268>.

13. Chapman, R., et al., 2017. Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice. *PLoS One* 12 (3), e0173352. <https://doi.org/10.1371/journal.pone.0173352>. Edited by S. Wang.
14. Chapman, R., et al., 2020. Immunogenicity of HIV-1 vaccines expressing chimeric envelope glycoproteins on the surface of Pr55 gag virus-like particles. *Vaccines* 8 (1), 1–17. <https://doi.org/10.3390/vaccines8010054>.
15. Davenport, T.M., et al., 2011. Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. *J. Virol.* 85 (14), 7095–7107. <https://doi.org/10.1128/JVI.00411-11>.
16. Decroly, E., et al., 1994. The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-1 TM). *J. Biol. Chem.* 269 (16), 12240–12247. [https://doi.org/10.1016/S0021-9258\(17\)32707-2](https://doi.org/10.1016/S0021-9258(17)32707-2).
17. Ding, C., et al., 2021. Employing broadly neutralizing antibodies as a human immunodeficiency virus prophylactic & therapeutic application. *Front. Immunol.* 1–16. <https://doi.org/10.3389/fimmu.2021.697683>.
18. Doores, K.J., Burton, D.R., 2010. Variable loop glycan dependency of the broad and potent HIV-1 Neutralizing antibodies PG9 and PG16. *J. Virol.* 84 (20), 10510–10521. <https://doi.org/10.1128/JVI.00552-10>.
19. Ellenberger, D., et al., 2005. Comparative immunogenicity in rhesus monkeys of multiprotein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. *Virology* 340 (1), 21–32. <https://doi.org/10.1016/j.virol.2005.06.014>.
20. van Etten, B., et al., 2002. Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras. *Br. J. Cancer* 86 (3), 436–442. <https://doi.org/10.1038/sj.bjc.6600089>.
21. Fischer, W., et al., 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. *Nat. Med.* 13 (1), 100–106. <https://doi.org/10.1038/nm1461>.
22. Frimpong, K., Spector, S.A., 2000. Cotransduction of nondividing cells using lentiviral vectors. *Gene Ther.* 7 (18), 1562–1569. <https://doi.org/10.1038/sj.gt.3301283>.
23. Garrone, P., et al., 2011. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. *Sci. Transl.*
24. Med. 3 (94) <https://doi.org/10.1126/scitranslmed.3002330>. Gaschen, B., et al., 2002. Diversity considerations in HIV-1 vaccine selection. *Science* 296(5577), 2354–2360. <https://doi.org/10.1126/science.1070441>.
25. Gheysen, D., et al., 1989. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. *Cell* 59 (1), 103–112. [https://doi.org/10.1016/0092-8674\(89\)90873-8](https://doi.org/10.1016/0092-8674(89)90873-8).
26. Gibson, D.G., et al., 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat. Methods* 6 (5), 343–345. <https://doi.org/10.1038/nmeth.1318>.
27. Goepfert, P.A., et al., 2014. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified Vaccinia Ankara vaccines expressing HIV-1 virus-like particles. *J. Infect. Dis.* 210 (1), 99–110. <https://doi.org/10.1093/infdis/jiu003>.
28. Gorny, M.K., et al., 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. *J. Virol.* 66 (12), 7538–7542. <https://doi.org/10.1128/jvi.66.12.7538-7542>.
29. Gorny, M.K., et al., 2002. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. *J. Virol.* 76 (18), 9035–9045. <https://doi.org/10.1128/JVI.76.18.9035-9045.2002>.
30. Griffith, S.A., McCoy, L.E., 2021. To bnAb or not to bnAb: defining broadly neutralising antibodies against HIV-1. *Front. Immunol.* 12, 1–16. <https://doi.org/10.3389/fimmu.2021.708227>.
31. Hallenberger, S., et al., 1992. Inhibition of furin-

- mediated cleavage activation of HIV-1 glycoprotein gp160. *Nature* 360 (6402), 358–361. <https://doi.org/10.1038/360358a0>.
32. van Heuvel, Y., et al., 2021. Establishment of a novel stable human suspension packaging cell line producing ecotropic retroviral MLV(PVC-211) vectors efficiently transducing murine hematopoietic stem and progenitor cells. *J. Virol Methods* 297, 114243. <https://doi.org/10.1016/j.jviromet.2021.114243>.
 33. Iyer, S.S., et al., 2016. Virus-like particles displaying trimeric simian immunodeficiency virus (SIV) envelope gp160 enhance the breadth of DNA/modified Vaccinia virus Ankara SIV vaccine-induced antibody responses in rhesus macaques. *J. Virol.* 90 (19), 8842–8854. <https://doi.org/10.1128/JVI.01163-16>. Edited by F. Kirchhoff.
 34. Jaffray, A., et al., 2004. Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. *J. Gen. Virol.* 85 (2), 409–413. <https://doi.org/10.1099/vir.0.19396-0>.
 35. Janes, H.E., et al., 2017. Higher T-cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial. *J. Infect. Dis.* 215 (9), 1376–1385. <https://doi.org/10.1093/infdis/jix086>.
 36. Kiepiela, P., et al., 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. *Nat. Med.* 13 (1), 46–53. <https://doi.org/10.1038/nm1520>. K